Drug Trial Radar · NCT05593029
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
929
Actual
Start
Nov 9, 2022
Primary completion
Nov 6, 2025
Study completion Nov 13, 2025
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Oct 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate response to prior ADT therapy.
Conditions
- Major Depressive Disorder
Interventions
SEP-363856Drug
Tablet
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Montgomery Åsberg Depression Rating Scale (MADRS)Time frame: From baseline to week 14
Locations
77 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Scottsdale Clinical Research
Scottsdale, Arizona
DelSol Research
Tucson, Arizona
Pillar Clinical Research
Bentonville, Arkansas
ProScience Research Group
Culver City, California
Wr-Pri, Llc
Encino, California
Collaborative NeuroScience Research , LLC
Garden Grove, California
Alliance Research
Long Beach, California
ATP Clinical Research, Inc.
Orange, California
Anderson Clinical Research
Redlands, California
California Mental Behavioral Health
Santee, California
Schuster Medical Research Institute SMRI
Sherman Oaks, California
Viking Clinical Research
Temecula, California
Collaborative Neuroscience Research LLC
Torrance, California
Sunwise Clinical Research with is in Lafayette, CA
Walnut Creek, California
Institute of Living Hartford Hospital
Hartford, Connecticut
Clinical Neuroscience Solutions Inc.
Jacksonville, Florida
K2 Medical Research
Maitland, Florida
Central Miami Medical Institute
Miami, Florida
Clinical Neuroscience Solutions Inc. dba CNS Healthcare
Orlando, Florida
Combined Research Orlando Phase I-IV
Orlando, Florida
K2 Medical Research
Tampa, Florida
Interventional Psychiatry of Tampa Bay
Tampa, Florida
Advanced Discovery Research LLC
Atlanta, Georgia
Renew Health Clinical Research
Snellville, Georgia
MetroMed Clinical Trials
Chicago, Illinois
AMR Convention Research
Warrenville, Illinois
Benchmark Research
Shreveport, Louisiana
Cenexel CBH (CBH Health)
Gaithersburg, Maryland
Copley Clinical
Boston, Massachusetts
Boston Clinical Trials
Roslindale, Massachusetts
Adams Clinical
Watertown, Massachusetts
Vitalix Clinical
Worcester, Massachusetts
Neurobehavioral Medicine Group
Bloomfield Hills, Michigan
Precise Research Centers
Flowood, Mississippi
Center for Emotional Fitness
Cherry Hill, New Jersey
Integrative Clinical Trials
Brooklyn, New York
Basil Clinical
Inwood, New York
Berman Clinical
New York, New York
Manhattan Behavioral Medicine PLLC
New York, New York
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.